Liberty Cap

Metadata

Regulatory Status

United States

• DEA Schedule: Psilocybin and psilocin are Schedule I controlled substances under the Controlled Substances Act (1970). P. semilanceata is not native to much of the United States but is occasionally found in the Pacific Northwest. Possession of the mushroom constitutes possession of a Schedule I substance.
• FDA status: No approved psilocybin drug product. FDA breakthrough therapy designations for psilocybin (COMPASS Pathways for treatment-resistant depression, 2018; Usona Institute for major depressive disorder, 2019) apply to synthetic psilocybin formulations, not whole mushroom products.
• State/local: Oregon (Measure 109, 2020) and Colorado (Proposition 122, 2022) have legalized or decriminalized psilocybin in therapeutic or personal use contexts. These laws do not distinguish between psilocybin source species.

European Union

• Status: Psilocybin is controlled in all EU member states. P. semilanceata is the most commonly encountered wild psilocybin mushroom in Europe, growing abundantly in grasslands across the UK, Ireland, Scandinavia, the Benelux countries, Germany, France, and other temperate regions. Fresh mushroom collection for personal use exists in a legal gray area in some jurisdictions but is explicitly prohibited in most.
• Netherlands: Psilocybin mushrooms (including P. semilanceata) are banned since 2008. Psilocybin-containing truffles (P. tampanensis) remain legal, but P. semilanceata does not produce sclerotia and is therefore not available through legal channels.
• United Kingdom: Psilocybin is a Class A drug under the Misuse of Drugs Act 1971. Fresh P. semilanceata mushrooms were legal until the Drugs Act 2005 closed the “fresh mushroom loophole.” P. semilanceata is the most commonly seized psilocybin mushroom species in UK forensic casework.

Scandinavia

• Sweden, Norway, Finland, Denmark: Psilocybin mushrooms are controlled substances. P. semilanceata is extremely common in Scandinavian grasslands and is the primary species involved in psilocybin-related incidents in Nordic countries.

Australia and New Zealand

• Australia: Psilocybin rescheduled to Schedule 8 (July 2023) for authorized psychiatric use, but this applies only to synthetic psilocybin administered by authorized psychiatrists, not to wild mushroom material. P. semilanceata is found in southeastern Australia.
• New Zealand: P. semilanceata is found in pastoral environments. Psilocybin is a Class A controlled substance.

Japan

• Status: Psilocybin and psilocin are controlled under the Narcotics and Psychotropics Control Act. P. semilanceata has been reported from Japan but is not common.

Conditions & Indications

Primary: Treatment-Resistant Depression and Major Depressive Disorder (Psilocybin Evidence)

• Treatment-resistant depression (TRD): Clinical trials using synthetic psilocybin have demonstrated significant efficacy. COMPASS Pathways’ Phase 3 trials (COMP005, COMP006) showed that 25 mg synthetic psilocybin with psychological support produced significant MADRS score reduction vs. 1 mg control. These results apply to psilocybin as a compound, which is the same active molecule present in P. semilanceata.
• Major depressive disorder (MDD): Johns Hopkins Phase 2 trial (Davis et al., 2021) showed 71% response rate at 4 weeks. Usona Institute Phase 2 trial (JAMA, 2023) confirmed rapid and sustained antidepressant effects with 25 mg psilocybin.
• Species-specific note: No clinical trial has used P. semilanceata-derived psilocybin. However, the psilocybin molecule is identical regardless of source. The high psilocybin concentration in P. semilanceata (0.98—1.28% dry weight) means a relatively small quantity of dried mushroom material would deliver a clinically relevant dose.

Secondary: End-of-Life Anxiety, Substance Use Disorders

• Cancer-related distress: Landmark trials at Johns Hopkins (Griffiths et al., 2016) and NYU (Ross et al., 2016) demonstrated rapid, sustained reductions in anxiety and depression in cancer patients using synthetic psilocybin.
• Tobacco cessation: Johns Hopkins pilot study showed 80% abstinence at 6 months with psilocybin-assisted therapy (Johnson et al., 2014).
• Alcohol use disorder: Bogenschutz et al. (2022, JAMA Psychiatry) demonstrated significant reduction in heavy drinking days with psilocybin vs. active placebo.

Emerging/Preclinical

• Cluster headache: Retrospective surveys and case reports suggest psilocybin may abort cluster headache cycles and extend remission. Controlled trials are pending. Some patient reports specifically reference P. semilanceata as a source species used for self-treatment in European contexts.
• Obsessive-compulsive disorder: Small pilot study (Moreno et al., 2006) showed marked OCD symptom reduction with psilocybin.
• Neuroplasticity: Psilocybin promotes dendritic spine growth and synaptogenesis in animal models (Shao et al., 2021).
• Baeocystin pharmacology: P. semilanceata’s notably high baeocystin content raises the question of whether baeocystin contributes to the overall pharmacological profile. Baeocystin (4-phosphoryloxy-N-methyltryptamine) is a monomethyl analog of psilocybin with less well-characterized receptor pharmacology. A 2019 study (Sherwood et al.) found baeocystin did not produce head-twitch response in mice (a behavioral proxy for 5-HT2A activation), suggesting it may have a different or attenuated pharmacological profile compared to psilocybin. [NEEDS-RESEARCH]

Mechanism of Action

Primary Mechanisms

1. 5-HT2A receptor agonism via psilocin: Psilocybin from P. semilanceata is dephosphorylated by alkaline phosphatase in the gut and liver to psilocin (4-hydroxy-DMT), which is a partial agonist at serotonin 5-HT2A receptors densely expressed on cortical layer V pyramidal neurons. Activation triggers Gq/11-mediated signaling, phospholipase C activation, and increased glutamate release in the prefrontal cortex, producing altered perception, cognition, and emotional processing. This mechanism is identical regardless of the Psilocybe source species.

2. Default mode network (DMN) disruption: Psilocin decreases activity and functional connectivity within the default mode network, associated with self-referential processing and rumination. This disruption correlates with ego dissolution and is hypothesized to enable cognitive “resetting” in depression and addiction (Carhart-Harris et al., 2012, 2016).

3. Neuroplasticity promotion: Psilocybin increases brain-derived neurotrophic factor (BDNF) levels and promotes dendritic spine growth and synaptogenesis in cortical neurons. Single-dose administration produced spine density increases lasting at least one month in mice (Shao et al., 2021). This structural plasticity may underlie sustained therapeutic effects.

4. Increased global brain connectivity: Psilocin produces increased entropy and cross-network communication between brain regions, enabling cognitive and emotional flexibility. This “entropic brain” state may help disrupt rigid thought patterns characteristic of depression and obsessive-compulsive conditions.

Secondary Mechanisms

• 5-HT2C and 5-HT1A activity: Psilocin acts at multiple serotonin receptor subtypes, contributing to anxiolytic effects and downstream dopaminergic modulation.
• Anti-inflammatory effects: Psilocybin reduces peripheral inflammatory markers (TNF-alpha, IL-6) in preclinical models, potentially relevant to the neuroinflammatory hypothesis of depression.
• Baeocystin contribution: The pharmacological role of baeocystin, which is present at unusually high concentrations in P. semilanceata, remains poorly characterized. If baeocystin has 5-HT receptor activity (even attenuated relative to psilocybin), it could modulate the overall subjective and therapeutic profile in a species-specific manner. Current evidence does not confirm this hypothesis. [NEEDS-RESEARCH]
• Phenylethylamine: Trace amounts of phenylethylamine (PEA) have been detected in P. semilanceata. PEA is a trace amine with stimulant properties, but its contribution at the concentrations present is likely negligible.

Clinical Evidence Summary

Species-Specific Analytical Studies

Psilocybin Clinical Trials (Synthetic Compound, Applicable to All Psilocybin Sources)

Evidence Limitations

• No clinical trials with P. semilanceata: All clinical evidence is derived from synthetic psilocybin. While the active compound is identical, whole-mushroom pharmacology (including the contribution of baeocystin, norbaeocystin, and other minor alkaloids) has not been clinically evaluated.
• “Entourage effect” hypothesis: Some researchers have proposed that the combination of tryptamine alkaloids in whole Psilocybe mushrooms may produce different subjective or therapeutic effects than pure psilocybin. This hypothesis is unproven and difficult to test given the controlled-substance status of whole mushroom material.
• Variability within species: While P. semilanceata shows less psilocybin variability than P. cubensis, concentrations still vary with geographic location, altitude, substrate, and season. This variability makes reliable dosing with wild-collected material difficult.
• Blinding challenges: The intense subjective effects of psilocybin make clinical trial blinding problematic, as acknowledged in all major trials.
• Psychological support confound: Clinical trials combine psilocybin with extensive therapeutic support (preparation, guided sessions, integration). The contribution of the compound versus the therapeutic context is not fully separable.

Safety Profile

General Assessment

The safety profile of P. semilanceata is governed primarily by its psilocybin content and is therefore substantially similar to that of other psilocybin-containing mushrooms, particularly P. cubensis. Psilocybin has very low physiological toxicity, with no confirmed deaths from psilocybin overdose in the clinical or forensic literature. The primary risks are psychological: challenging experiences, anxiety, paranoia, and rare prolonged psychotic episodes in vulnerable individuals. Additional risks specific to P. semilanceata include misidentification (several small brown mushrooms with different toxicity profiles grow in similar habitats) and unpredictable dosing from wild-collected material.

Contraindications

• Psychotic spectrum disorders: Personal or first-degree family history of schizophrenia, schizoaffective disorder, or bipolar I disorder. Risk of precipitating or exacerbating psychotic episodes.
• Concurrent serotonergic medications: SSRIs and SNRIs may attenuate effects; MAOIs are strictly contraindicated due to potentiation and serotonin syndrome risk. Lithium is contraindicated due to seizure risk.
• Cardiovascular disease: Transient mild-to-moderate increases in heart rate (+5—15 bpm) and blood pressure (+10—20 mmHg systolic).
• Pregnancy and lactation: Contraindicated due to serotonergic mechanism and unknown teratogenic potential.

Drug Interactions

• SSRIs/SNRIs: Attenuate psilocybin effects; rare serotonin toxicity reports. Clinical trials typically require 2-week washout (5 weeks for fluoxetine).
• MAOIs: Potentiate and prolong effects. Significantly elevated serotonin syndrome risk. Strictly contraindicated.
• Lithium: Case reports of seizures with combined use. Contraindicated.
• Stimulants: May increase cardiovascular stress.
• CYP2D6 inhibitors: Psilocin is partially metabolized by CYP2D6; strong inhibitors could theoretically increase exposure.

Side Effects

• Common (>10%): Headache (most common, typically transient and mild), nausea, transient anxiety during onset, emotional distress during experience, fatigue.
• Occasional (1—10%): Paranoia, confusion, dizziness, visual disturbances persisting briefly post-experience, elevated blood pressure, tachycardia.
• Rare (<1%): Prolonged psychotic symptoms (predominantly in predisposed individuals), hallucinogen persisting perception disorder (HPPD), suicidal ideation.

Identification Hazards Specific to P. semilanceata

• Misidentification risk: P. semilanceata is a small, nondescript brown mushroom (LBM — “little brown mushroom”) growing in grasslands. It can be confused with several toxic or non-psychoactive species:
  • Galerina marginata (deadly — contains amatoxins): Superficially similar in size and color, though G. marginata is typically wood-associated rather than grassland-associated. Spore print color differs (brown for Galerina vs. dark purple-brown for P. semilanceata).
  • Inocybe species (muscarine-containing): Some grassland Inocybe species resemble P. semilanceata.
  • Conocybe species: Small brown grassland mushrooms; some contain amatoxins.
• Expert identification is essential for anyone encountering wild specimens. Spore print, microscopy, and habitat assessment are required for definitive identification.

Toxicology

• Acute toxicity: Very low. No deaths from psilocybin toxicity confirmed. Estimated human LD50 approximately 280 mg/kg (extrapolated from animal data), far exceeding any dose achievable from mushroom ingestion.
• Organ toxicity: No evidence of hepatotoxicity, nephrotoxicity, or cardiotoxicity.
• Dependence potential: Very low. Rapid tolerance (tachyphylaxis) develops within days. No physical withdrawal syndrome. Not considered addictive.
• Neurotoxicity: No evidence at psychoactive doses. Preclinical evidence suggests neuroprotective rather than neurotoxic effects.

Clinical Dosage

Important Legal Disclaimer

Psilocybe semilanceata is a controlled substance in virtually all jurisdictions. The following dosage information is provided for toxicological, forensic, and clinical research reference only, not as a therapeutic recommendation. All clinical applications of psilocybin should be conducted within approved research protocols or legally authorized therapeutic frameworks.

Psilocybin Content Reference

• Psilocybin concentration: 0.98—1.28% dry weight (mean approximately 1.0%)
• Baeocystin concentration: approximately 0.36% dry weight
• Individual mushroom weight: Approximately 0.3—0.5 g fresh (0.03—0.05 g dried per mushroom)
• Estimated psilocybin per dried mushroom: 0.3—0.6 mg per individual mushroom

Equivalent Doses (Theoretical, Not Clinical Recommendations)

• Clinical trial equivalent (25 mg psilocybin): Approximately 2.0—2.5 g dried P. semilanceata material, based on mean psilocybin content of 1.0% dry weight. This is considerably less material than the equivalent dose of P. cubensis (approximately 3.5—5 g dried), reflecting P. semilanceata’s higher psilocybin concentration.
• Sub-perceptual range (“microdose”): 0.1—0.3 g dried (approximately 1—3 mg psilocybin). Clinical evidence for microdosing efficacy is weak and inconclusive.

Critical Dosing Considerations

• Natural variability: Psilocybin content varies with geographic location, altitude, growing conditions, and season. Individual mushrooms within a single collection can differ substantially.
• Baeocystin contribution: The high baeocystin content may modify the overall subjective experience compared to pure psilocybin or lower-baeocystin species, though this has not been systematically studied.
• Set and setting: Clinical trial protocols emphasize the critical importance of therapeutic context (comfortable environment, trained therapist presence, preparatory and integration sessions). These elements are considered essential to safety and efficacy.
• No established safe dose outside clinical supervision for psychiatric indications.

Sources

• Gartz J. Extraction and analysis of indole derivatives from fungal biomass. J Basic Microbiol. 1994;34(1):17-22
• Stijve T, Kuyper TW. Occurrence of psilocybin in various higher fungi from several European countries. Planta Med. 1985;51(5):385-387
• Christiansen AL, Rasmussen KE, Tonnesen F. Determination of psilocybin in Psilocybe semilanceata using high-performance liquid chromatography on a silica column. J Chromatogr. 1981;210(1):163-167
• Gotvaldova K, Hajkova K, Borovicka J, Eliska P, Jurok R, Cihlova K, Kuchař M. Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis. Drug Test Anal. 2021;13(2):439-446
• Lenz C, Sherwood A, Decker R, et al. Biosynthesis of psilocybin and related compounds in fungi. J Nat Prod. 2020;83(4):1065-1070
• Sherwood AM, Halberstadt AL, Klein AK, et al. Synthesis and biological evaluation of tryptamines found in hallucinogenic mushrooms: norbaeocystin, baeocystin, norpsilocin, and aeruginascin. J Nat Prod. 2020;83(2):461-467
• Stamets P. Psilocybin Mushrooms of the World: An Identification Guide. Ten Speed Press; 1996
• Guzmán G. Hallucinogenic mushrooms in Mexico: An overview. Econ Bot. 2008;62(3):404-412
• Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481-489
• Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648
• Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012;109(6):2138-2143
• Shao LX, Liao C, Greber I, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535-2544.e4
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. J Psychopharmacol. 2016;30(12):1181-1197
• Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder. JAMA Psychiatry. 2022;79(10):953-962
• Watling R. A revision of Psilocybe semilanceata and related species. Trans Br Mycol Soc. 1977;68(3):337-360
• Borovicka J, Obornik M, Stribna J, Gryndler M, Fricova R. Molecular phylogenetics of Psilocybe cyanescens complex. Mycologia. 2015;107(6):1159-1171

Connections

• Psilocybe cubensis: Psilocybe cubensis is the most widely studied psilocybin mushroom and the source of nearly all clinical trial data. While both species produce psilocybin via the same biosynthetic pathway, P. semilanceata typically contains higher psilocybin concentrations (0.98—1.28% vs. 0.14—1.86% dry weight) and notably higher baeocystin levels. P. cubensis is a tropical/subtropical dung-colonizing species amenable to indoor cultivation, whereas P. semilanceata is a temperate grassland saprotroph that has resisted cultivation attempts, making it exclusively wild-harvested.
• Amanita muscaria: Fly Agaric represents a pharmacologically distinct psychoactive mushroom class. While P. semilanceata acts through serotonin 5-HT2A receptor agonism (classical psychedelic), A. muscaria acts through GABA-A receptor agonism (muscimol), producing sedative-dissociative rather than psychedelic effects. This distinction is frequently misunderstood in popular culture.
• Lion’s Mane: Lion’s Mane promotes neuroplasticity through NGF/BDNF stimulation via hericenones and erinacines. The neuroplasticity mechanisms are complementary to psilocybin’s 5-HT2A-mediated dendritic spine growth. Anecdotal “stacking” protocols combining sub-perceptual psilocybin with Lion’s Mane are popular but lack clinical evidence.
• Claviceps purpurea: Ergot produces ergot alkaloids including lysergic acid, the precursor to LSD. Both ergot alkaloids and psilocybin are indole-derived compounds acting at serotonin receptors, representing convergent evolution of serotonergic pharmacology in phylogenetically distant fungi.
• Ecological context: Unlike most medicinal mushrooms covered in this reference, P. semilanceata is a wild grassland saprotroph associated with the root zones of grasses (particularly Agrostis, Festuca, Poa) in nutrient-poor, unfertilized pastures. Agricultural intensification, nitrogen fertilization, and habitat loss threaten populations in some traditional habitats, raising conservation questions for a species that cannot be cultivated.